Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Subjects
NCT03001115 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 17
Last updated 2020-06-12
Summary
The objective of this study is to evaluate the safety profile of Adalimumab for Hidradenitis Suppurativa (HS) participants in normal medical practice.
Conditions
- Hidradenitis Suppurativa (HS)
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
AbbVie Inc. · AbbVie
Eligibility
- Min Age
- 18 Years
- Max Age
- 99 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-03-10
- Primary Completion
- 2019-07-31
- Completion
- 2019-07-31
Countries
- South Korea
Study Locations
More Related Trials
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
NCT05889182 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of LAD191 in Adults With Hidradenitis Suppurativa
NCT07151937 ·Status: RECRUITING ·Phase: PHASE2
-
Effectiveness of Adalimumab in Moderate to Severe HidrAdenitis SuppuRativa Patients - a Multi cOuNtry studY in Real Life Setting
NCT02786576 ·Status: COMPLETED
-
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
NCT01468233 ·Status: COMPLETED ·Phase: PHASE3
-
Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa
NCT01635764 ·Status: COMPLETED ·Phase: PHASE3
-
Real-World Outcome of Psoriasis Subjects in Korea on Adalimumab
NCT03099083 ·Status: COMPLETED
-
A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms
NCT04430855 ·Status: COMPLETED ·Phase: PHASE2
-
Cost-effectiveness of Adalimumab and Surgery vs Adalimumab in HS
NCT03221621 ·Status: UNKNOWN ·Phase: PHASE4
-
To Assess the Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
NCT00827996 ·Status: COMPLETED ·Phase: PHASE2
-
A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT03926169 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
NCT06799000 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis
NCT05391061 ·Status: RECRUITING
-
Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00646191 ·Status: COMPLETED ·Phase: PHASE2
-
Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00645814 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug
NCT03104374 ·Status: COMPLETED ·Phase: PHASE3
-
A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 6 Years and Older With Moderate to Severe Plaque Psoriasis
NCT03218488 ·Status: ACTIVE_NOT_RECRUITING
-
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
NCT03104400 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis
NCT00195689 ·Status: COMPLETED ·Phase: PHASE3
-
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
NCT06118411 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06212999 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Efficacy and Safety of Dupilumab in Patients With Bullous Pemphigoid
NCT05649579 ·Status: COMPLETED
-
Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06118099 ·Status: TERMINATED ·Phase: PHASE2
-
Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00195676 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis
NCT01646073 ·Status: COMPLETED ·Phase: PHASE3
-
A Double-blind Placebo-controlled Randomized Trial Evaluating the Efficacy and Safety of a Novel HSP90 Inhibitor (RGRN-305) in the Treatment of Moderate to Severe Hidradenitis Supppurativa.
NCT05286567 ·Status: COMPLETED ·Phase: PHASE1